Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both man and woman who is over 19 years old~* Patient with dyslipidemia and hypertension~* Written informed consent~Exclusion Criteria:~* Triglyceride ≥ 400 mg/dL at screening~* Hypertensive patients who need antihypertensive medication except Amlodipine, β-blockers, RAS inhibitors~* sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg~* A history of rhabdomyolysis, myopathy~* Patient with hypersensitivity to Statin or Amlodipine~* Patients undergoing eGFR \<30 mL/min/1.73 m2 (MDRD) at screening~* AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper limit of normal range) or active liver disease~* Creatine kinase (CK) level ≥ 5x ULN (upper limit of normal range)~* Contraindications stated in the Label of Rosuampin or Caduet~* Those participating in other clinical trials for investigational products at screening~* Patients deemed to be ineligible to participate in the trial by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuampin 10/5mg (Type: EXPERIMENTAL): Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
- Rosuampin 20/5mg (Type: EXPERIMENTAL): Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
- Amlodipine/Atorvastatin 5/20mg (Type: ACTIVE_COMPARATOR): Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).